Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

iCAD/Confirma alliance

This article was originally published in The Gray Sheet

Executive Summary

July launch is planned for iCAD's Second Look 500M computer aided detection (CAD) system, combining film-based mammography review with Confirma's CADstream magnetic resonance imaging (MRI) review technology to aid breast cancer detection, firms announce June 3. The device will cost $219,900, with a per-procedure charge of about $150 for each breast MR/CAD analysis, according to iCAD. CADstream also is available as an upgrade. Separately, iCAD's Second Look200 CAD system gains FDA go-ahead to detect breast cancers, offering up to 94% sensitivity, the firm says. Priced below $70,000, the system is intended for smaller mammography centers that perform less than 15 cases per day, iCAD says. Second Look 200 will be available under iCAD's ClickCAD fee-per-procedure program (1"The Gray Sheet" May 10, 2004, p. 27)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel